Journal of Neurology

, Volume 265, Issue 11, pp 2666–2671 | Cite as

Treatment course and outcomes after revascularization surgery for moyamoya disease in adults

  • Amanda Kahn
  • Gurmeen Kaur
  • Laura Stein
  • Stanley Tuhrim
  • Mandip S. DhamoonEmail author
Original Communication



International trials suggest benefit of revascularization surgery (RS) for moyamoya disease (MMD). However, nationally representative US data on demographics and outcomes after RS in MMD are lacking.


To estimate causes and rates of readmission after RS for MMD.


In the Nationwide Readmissions Database, index admissions for ECICB for MMD and readmissions for ischemic stroke (IS), subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH) were identified using validated International Classification of Diseases, Ninth Revision, Clinical Modification codes. We summarized demographics and comorbidities, and calculated 30-, 60-, and 90-day readmission rates per 100,000 index admissions.


Among 201 index admissions for RS for MMD, mean age (SD) was 41.7 (12.6) years; 75% were female; 24% had diabetes; 53% had hypertension; 40% had hypercholesterolemia; 3% had ICH; 16% had IS; and 1% had SAH. RS was performed at large hospitals in 83%, urban hospitals in 85%, and teaching hospitals in 97%. 80% were discharged home. 34% had a readmission during follow-up. Leading reasons for readmission up to 90 days included MMD (62%), postoperative infection (10%), sickle cell crisis (4%), ischemic stroke (4%), epilepsy (2%), subdural hemorrhage (2%) and headache (2%). Readmission rates (per 100,000 index admissions) were 559 at 30 days, 1829 at 60 days, and 2027 at 90 days for IS. There were no readmissions for SAH or ICH.


This analysis of nationally representative US data suggests that although readmission after RS for MMD is not uncommon, cerebral hemorrhagic events during the 90-day postoperative period are rare.


Moyamoya disease Stroke Utilization 




Compliance with ethical standards

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical standards

This research was approved by the Mount Sinai IRB ethics committee and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.


  1. 1.
    Arias EJ, Derdeyn CP, Dacey RG Jr, Zipfel GJ (2014) Advances and surgical considerations in the treatment of moyamoya disease. Neurosurgery 74(Suppl 1):S116–S125CrossRefGoogle Scholar
  2. 2.
    Baram D, Daroowalla F, Garcia R, Zhang G, Chen JJ, Healy E et al (2008) Use of the all patient refined-diagnosis related group (APR-DRG) risk of mortality score as a severity adjustor in the medical ICU. Clin Med Circ Respir Pulm Med 2:19–25Google Scholar
  3. 3.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefGoogle Scholar
  4. 4.
    de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56:221–229CrossRefGoogle Scholar
  5. 5.
    Duan L, Bao XY, Yang WZ, Shi WC, Li DS, Zhang ZS et al (2012) Moyamoya disease in China: its clinical features and outcomes. Stroke 43:56–60CrossRefGoogle Scholar
  6. 6.
    Fujimura M, Tominaga T (2012) Lessons learned from moyamoya disease: outcome of direct/indirect revascularization surgery for 150 affected hemispheres. Neurol Med Chir (Tokyo) 52:327–332CrossRefGoogle Scholar
  7. 7.
    Gross BA, Du R (2013) Adult moyamoya after revascularization. Acta Neurochir (Wien) 155:247–254CrossRefGoogle Scholar
  8. 8.
    Guzman R, Lee M, Achrol A, Bell-Stephens T, Kelly M, Do HM et al (2009) Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article. J Neurosurg 111:927–935CrossRefGoogle Scholar
  9. 9.
    Houkin K, Nakayama N, Kuroda S, Ishikawa T, Nonaka T (2004) How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst 20:734–741PubMedGoogle Scholar
  10. 10.
    Imaizumi T, Hayashi K, Saito K, Osawa M, Fukuyama Y (1998) Long-term outcomes of pediatric moyamoya disease monitored to adulthood. Pediatr Neurol 18:321–325CrossRefGoogle Scholar
  11. 11.
    Kainth D, Chaudhry SA, Kainth H, Suri FK, Qureshi AI (2013) Epidemiological and clinical features of moyamoya disease in the USA. Neuroepidemiology 40:282–287CrossRefGoogle Scholar
  12. 12.
    Karasawa J, Kikuchi H, Furuse S, Kawamura J, Sakaki T (1978) Treatment of moyamoya disease with STA-MCA anastomosis. J Neurosurg 49:679–688CrossRefGoogle Scholar
  13. 13.
    Kawaguchi S, Okuno S, Sakaki T (2000) Effect of direct arterial bypass on the prevention of future stroke in patients with the hemorrhagic variety of moyamoya disease. J Neurosurg 93:397–401CrossRefGoogle Scholar
  14. 14.
    Kazumata K, Ito M, Uchino H, Nishihara H, Houkin K (2017) Proposal for a prospective registry for Moyamoya disease in Japan. Neurol Medico-Chirurgica 57:66–72CrossRefGoogle Scholar
  15. 15.
    Kim T, Oh CW, Kwon OK, Hwang G, Kim JE, Kang HS et al (2016) Stroke prevention by direct revascularization for patients with adult-onset moyamoya disease presenting with ischemia. J Neurosurg 124:1788–1793CrossRefGoogle Scholar
  16. 16.
    Kraemer M, Heienbrok W, Berlit P (2008) Moyamoya disease in Europeans. Stroke 39:3193–3200CrossRefGoogle Scholar
  17. 17.
    Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y (2005) Incidence and clinical features of disease progression in adult moyamoya disease. Stroke 36:2148–2153CrossRefGoogle Scholar
  18. 18.
    Lee DJ, Liebeskind DS (2011) Characterization of inpatient moyamoya in the United States: 1988–2004. Front Neurol 2:43CrossRefGoogle Scholar
  19. 19.
    Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T et al (2014) Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 45:1415–1421CrossRefGoogle Scholar
  20. 20.
    Narisawa A, Fujimura M, Tominaga T (2009) Efficacy of the revascularization surgery for adult-onset moyamoya disease with the progression of cerebrovascular lesions. Clin Neurol Neurosurg 111:123–126CrossRefGoogle Scholar
  21. 21.
    Parikh NS, Cool J, Karas MG, Boehme AK, Kamel H (2016) Stroke risk and mortality in patients with ventricular assist devices. Stroke 47:2702–2706CrossRefGoogle Scholar
  22. 22.
    Shen Y (2003) Applying the 3M all patient refined diagnosis related groups grouper to measure inpatient severity in the VA. Med Care 41:Ii103–I110PubMedGoogle Scholar
  23. 23.
    Starke RM, Crowley RW, Maltenfort M, Jabbour PM, Gonzalez LF, Tjoumakaris SI et al (2012) Moyamoya disorder in the United States. Neurosurgery 71:93–99CrossRefGoogle Scholar
  24. 24.
    Tirschwell DL, Longstreth WT Jr (2002) Validating administrative data in stroke research. Stroke 33:2465–2470CrossRefGoogle Scholar
  25. 25.
    Titsworth WL, Scott RM, Smith ER (2016) National analysis of 2454 pediatric Moyamoya admissions and the effect of hospital volume on outcomes. Stroke 47:1303–1311CrossRefGoogle Scholar
  26. 26.
    Uchino K, Johnston SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington State and California. Neurology 65:956–958CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Amanda Kahn
    • 1
  • Gurmeen Kaur
    • 2
  • Laura Stein
    • 2
  • Stanley Tuhrim
    • 2
  • Mandip S. Dhamoon
    • 2
    Email author
  1. 1.Duke UniversityDurhamUSA
  2. 2.Department of NeurologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations